Navigation Links
t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
Date:11/25/2008

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is now prepared to enter Phase III. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.

    Contact

    Manfred Ruediger, CEO
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
   http://www.t2cure.com


'/>"/>
SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
3. Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
4. Affitech Acquires Pharmexas Diabody Technology
5. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
6. CPA Acquires Renowned German Patent Research Specialist, SVPG
7. Circassia Acquires North American and Japanese Rights to Dopexamine
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
11. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... 4MD Medical ... Women’s Association, offering an exclusive scholarship opportunity for women across the country to earn ... individual as they continue their education,” said Rochelle Schwartz, Founder of 4MD Medical and ...
(Date:7/7/2015)... 7, 2015  Neogen Corporation (NASDAQ: NEOG ) ... expand its relationship with Illumina (NASDAQ: ILMN ), ... agreement, Illumina will market and sell arrays with Neogen,s ... BeadArray technology, to the global agrigenomics community. ... its GeneSeek ® genomics laboratory in ...
(Date:7/7/2015)... ... July 07, 2015 , ... uBiome, the leading microbial genomics company, is offering ... kits and full 16S laboratory analysis. The goal is to fast-track a study with ... access to their own dashboard, enabling them to view and compare the results of ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... CSM, a ... team as Vice President of Finance. Morse has an extensive background in financial management ... to the CSM team. In his new role, Morse will oversee all financial areas ...
Breaking Biology Technology:4MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 24MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 3Neogen signs commercialization agreement with Illumina 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3CSM Appoints Michael Morse as Vice President of Finance 2
... 9 Kendle (Nasdaq: KNDL ), ... announced Chief Operating Officer Christopher Bergen will participate ... March 10 as well as the Raymond James ... http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ) Barclays ...
... Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged ... announced that the U.S. Food and Drug Administration (FDA) ... Adhesion Barrier for use in pediatric cardiac surgery patients. ... over the surface of the heart at the conclusion ...
... Alliance, the leading management consulting firm specializing in ... Joe Dillon has joined its Business Development Practice. ... Business Development Practice to help pharmaceutical and biotech ... related to in- and out-licensing, opportunity assessment, and ...
Cached Biology Technology:Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 3Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... A recently released scientific paper authored by San ... leading causes of death of the endangered California condor ... being the primary factor in juvenile and adult birds. ... California condors at all release sitesCalifornia, Arizona and Baja, ...
... new way to create electromagnetic Terahertz (THz) waves or T-rays ... the study, published recently in the journal Nature Photonics ... T-rays could be used to make better medical scanning gadgets ... ,tricorder, scanner used in Star Trek. In the study, ...
... Jan. 20, 2012   Cell Therapeutics, Inc. ("CTI") (NASDAQ ... the European Medicines Agency,s ("EMA") Committee for Medicinal Products ... opinion on CTI,s Marketing Authorization Application ("MAA") for Pixuvri ... work with the CHMP on the Summary of Product ...
Cached Biology News:Scientific paper shows California condor still threatened by human activities 2T-rays technology could help develop Star Trek-style hand-held medical scanners 2T-rays technology could help develop Star Trek-style hand-held medical scanners 3Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 2Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 3
... is the first all-inclusive collection of key ... Expression System. Methods developed by the leaders ... step-by-step protocols. This book will guide you ... strain construction and analysis, to production of ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
Biology Products: